This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rapid Renal Sympathetic Denervation for Resistant Hypertension II (RAPID II)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Medtronic Endovascular Identifier:
First received: September 6, 2013
Last updated: August 14, 2015
Last verified: August 2015
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.

Condition Intervention Phase
Resistant Hypertension Uncontrolled Hypertension Renal Artery Ablation Device: Renal Denervation (OneShot™ Renal Denervation System) Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II

Further study details as provided by Medtronic Endovascular:

Primary Outcome Measures:
  • Major adverse event (MAE) rate through 30 days post randomization [ Time Frame: 30 days ]
  • Change in office systolic blood pressure (SBP) from baseline to 6 months post-randomization [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Acute Procedural Safety [ Time Frame: 30 days ]
  • Chronic procedural safety [ Time Frame: 6 months ]
  • Reduction in SBP by >10 mmHg at 6 months [ Time Frame: 6 months ]
  • Changes in office SBP and diastolic blood pressure (DBP) from baseline to follow-up visits [ Time Frame: 6, 12, 24, and 36 months ]

Enrollment: 0
Study Start Date: September 2013
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Renal Denervation
Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
Device: Renal Denervation (OneShot™ Renal Denervation System)
Other Names:
  • OneShot Ablation system
  • Catheter-based renal denervation
No Intervention: Optimal Medical Therapy
Subjects randomized to the control arm will be maintained on antihypertensive medications.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individual has a systolic blood pressure ≥ 160 mmHg based on an average of three office blood pressure readings.
  • Stable drug regimen including three or more anti-hypertensive medications including a diuretic

Exclusion Criteria:

  • Renal anatomy unsuitable for treatment
  • Presence of hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous
  • Patient has Type I diabetes
  • Has scheduled or planned surgery within the next 6 months
  • Individual is pregnant nursing or plans to be pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01939392

Hospital San Raffaele
Milano, Italy
Sponsors and Collaborators
Medtronic Endovascular
Principal Investigator: Dierk Scheinert, MD Park-Krankenhaus Liepzig
Principal Investigator: Guiseppe Mancia, MD Universita Minano-Bicocca, Ospedale San Gerardo di Monza
  More Information

Responsible Party: Medtronic Endovascular Identifier: NCT01939392     History of Changes
Other Study ID Numbers: CP-1003
Study First Received: September 6, 2013
Last Updated: August 14, 2015

Keywords provided by Medtronic Endovascular:
Resistant hypertension
Uncontrolled hypertension
Renal artery ablation

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on August 18, 2017